Table 4. Histologic parameters.
| Variable | G1 (N = 10) | G2 (N = 10) | G3 (N = 6) | G4 (N = 7) | G5 (N = 6) | P-value* |
|---|---|---|---|---|---|---|
| Apoptosis | 27.8 ± 8.5 | 20.9 ± 11.3 | 31.2 ± 11.8 | 35.0 ± 7.7 | 20.8 ± 3.5 | 0.019 |
| P-value** | 1.000/1.000/1.000/1.000† | 0.387/0.039/1.000†† | 1.000/0.599††† | 0.091†††† | - | |
| MVD | 10.3 ± 5.8 | 10.6 ± 4.5 | 19.2 ± 5.9 | 16.2 ± 7.5 | 21.0 ± 4.7 | 0.001 |
| P-value** | 1.000/0.050/0.439/0.009† | 0.063/0.535/0.012†† | 1.000/1.000††† | 1.000†††† | - |
Values are mean ± SD. G1, combined sorafenib and doxorubicin-microbubble group; G2, sorafenib-treated group; G3, doxorubicin-microbubble group; G4, doxorubicin treated group; G5, untreated control group; MVD, microvessel density.
*One-way analysis of variance (ANOVA)
**Post-hoc analysis of ANOVA
†G1 vs. G2 / G1 vs. G3 / G1 vs. G4 / G1 vs. G5
††G2 vs. G3 / G2 vs. G4 / G2 vs. G5
†††G3 vs. G4 / G3 vs. G5
††††G4 vs. G5.